Your browser is no longer supported. Please, upgrade your browser.
Settings
AERI Aerie Pharmaceuticals, Inc. daily Stock Chart
AERI [NASD]
Aerie Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.33 Insider Own1.20% Shs Outstand45.12M Perf Week12.37%
Market Cap967.37M Forward P/E- EPS next Y-2.32 Insider Trans177.63% Shs Float40.10M Perf Month11.49%
Income-196.00M PEG- EPS next Q-0.76 Inst Own- Short Float36.81% Perf Quarter-7.51%
Sales59.70M P/S16.20 EPS this Y-35.90% Inst Trans20.55% Short Ratio11.96 Perf Half Y-33.54%
Book/sh4.60 P/B4.66 EPS next Y26.60% ROA-62.10% Target Price41.56 Perf Year-46.47%
Cash/sh7.55 P/C2.84 EPS next 5Y- ROE-99.90% 52W Range17.15 - 50.10 Perf YTD-40.61%
Dividend- P/FCF- EPS past 5Y2.60% ROI-92.10% 52W High-57.39% Beta0.45
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin94.10% 52W Low24.49% ATR1.18
Employees353 Current Ratio5.40 Sales Q/Q153.40% Oper. Margin- RSI (14)60.79 Volatility6.14% 5.24%
OptionableYes Debt/Eq0.88 EPS Q/Q44.40% Profit Margin- Rel Volume0.29 Prev Close21.44
ShortableYes LT Debt/Eq0.88 EarningsNov 06 AMC Payout- Avg Volume1.23M Price21.35
Recom1.90 SMA2011.93% SMA506.68% SMA200-28.43% Volume294,318 Change-0.42%
Nov-07-19Reiterated H.C. Wainwright Buy $55 → $41
Oct-30-19Reiterated Needham Buy $54 → $48
Aug-08-19Reiterated Needham Buy $74 → $54
Aug-08-19Reiterated Cantor Fitzgerald Overweight $85 → $62
Mar-21-19Initiated Piper Jaffray Overweight $80
Jul-13-18Reiterated Needham Buy $76 → $86
Feb-16-18Resumed H.C. Wainwright Buy $78
Jan-26-18Initiated Seaport Global Securities Buy $78
Oct-24-17Initiated Guggenheim Buy $80
Oct-16-17Reiterated Needham Buy $65 → $76
Jul-20-17Reiterated Cantor Fitzgerald Overweight $56 → $62
May-25-17Reiterated Needham Buy $58 → $65
Mar-09-17Downgrade Raymond James Strong Buy → Mkt Perform
Mar-08-17Reiterated RBC Capital Mkts Outperform $54 → $55
Mar-08-17Reiterated Needham Buy $52 → $58
Feb-17-17Initiated ROTH Capital Buy $69
Nov-01-16Initiated Aegis Capital Buy
Oct-28-16Reiterated RBC Capital Mkts Outperform $48 → $49
Oct-06-16Reiterated Stifel Buy $50 → $55
Sep-20-16Initiated H.C. Wainwright Buy $66
Dec-09-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance Business Wire +5.91%
Dec-06-19 11:31AM  Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue? Zacks
Dec-04-19 09:19AM  Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy ? Insider Monkey +6.32%
Dec-03-19 06:15AM  Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe Business Wire
Dec-02-19 04:56AM  Did Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insiders Buy Up More Shares? Simply Wall St.
Nov-27-19 09:45AM  5 Strong Buy Biotech Stocks With More Than 80% Upside InvestorPlace
Nov-26-19 06:30AM  Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
06:30AM  Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-22-19 08:18AM  The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga
Nov-21-19 06:30AM  Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02% Business Wire
Nov-19-19 10:58AM  Aerie buys Spanish outfit as it moves toward profitability American City Business Journals
09:31AM  Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex Zacks
Nov-18-19 06:30AM  Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program Business Wire
Nov-12-19 07:30AM  Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference Business Wire
05:41AM  Edited Transcript of AERI earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 10:51AM  Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed Zacks -22.42%
07:18AM  The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga
Nov-06-19 06:05PM  Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire
Nov-05-19 06:30AM  Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan Business Wire
Oct-30-19 07:30AM  Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019 Business Wire
06:30AM  Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer Business Wire
Oct-29-19 10:33AM  Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Oct-28-19 06:13PM  Is Aerie Pharmaceuticals Inc (AERI) Going To Burn These Hedge Funds ? Insider Monkey +5.44%
Oct-25-19 06:40AM  Imagine Owning Aerie Pharmaceuticals (NASDAQ:AERI) While The Price Tanked 62% Simply Wall St.
Oct-24-19 06:30AM  Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule Business Wire
Oct-16-19 07:15PM  Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Oct-07-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer Business Wire
Sep-25-19 07:30AM  Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-23-19 01:20PM  Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa Zacks
Sep-20-19 06:30AM  Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union Business Wire
Sep-19-19 07:39AM  The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO Benzinga +5.87%
06:37AM  Will Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Need To Raise More Money? Simply Wall St.
06:30AM  Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its Athlone Ireland Facility Business Wire
Sep-16-19 11:46AM  Weekly CEO Buys Highlight GuruFocus.com +7.92%
Sep-10-19 09:36PM  Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aeries 1.50% Convertible Senior Notes Due 2024 Business Wire +8.26%
Sep-09-19 07:15PM  Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Bought $499,012 of Shares GuruFocus.com +8.77%
06:00AM  These 2 Biotech Stocks Are Seeing Insider Buying Activity TheStreet.com
Sep-06-19 02:42PM  Durham pharma embarks on $275M financial trade American City Business Journals
09:31AM  Aerie (AERI) Down 19.7% Since Last Earnings Report: Can It Rebound? Zacks
Sep-05-19 08:12AM  The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug Benzinga
Sep-04-19 08:20PM  Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024 Business Wire -9.31%
Sep-03-19 04:01PM  Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024 Business Wire -5.82%
Aug-26-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs Business Wire
Aug-20-19 06:30AM  Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Business Wire -5.78%
Aug-19-19 01:56PM  Zuckerberg Sells Shares of Facebook GuruFocus.com
Aug-08-19 04:08PM  This Biotech Crashed On 'Erroneous' Report Plus 2 Stocks That Diverged Investor's Business Daily +6.65%
09:25AM  Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance Zacks
09:02AM  Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability Simply Wall St.
01:50AM  Aerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 06:05PM  Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM  Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire
Jul-31-19 10:36AM  Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-28-19 09:23PM  Analysts Recommend Buying These 2 Falling Knives GuruFocus.com
Jul-25-19 07:30AM  Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019 Business Wire
Jul-18-19 06:26PM  Allergan Announces FDA Acceptance of Glaucoma Candidate NDA Zacks
08:22AM  Hatteras Ventures-backed firm adds fresh round of capital American City Business Journals
Jul-11-19 06:46AM  How a Durham firm stands to benefit from an unexpected break in a Japanese trial American City Business Journals
Jul-09-19 05:48PM  Aerie Completes Enrollment Under Rhopressa Study in Japan Zacks
06:30AM  Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule Business Wire
Jun-24-19 08:50AM  Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza Zacks
Jun-20-19 07:09PM  Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy? Insider Monkey
Jun-17-19 09:47PM  Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
06:30AM  Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting Business Wire
Jun-11-19 07:30AM  Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire
Jun-06-19 01:58PM  Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price? Simply Wall St. -6.09%
09:31AM  Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report? Zacks
May-28-19 07:30AM  Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference Business Wire
May-21-19 05:36PM  Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint Zacks
May-08-19 02:45PM  Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates Zacks +7.50%
May-07-19 10:46PM  Aerie Pharmaceuticals, Inc. (AERI) Q1 2019 Earnings Call Transcript Motley Fool -5.37%
06:15PM  Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:09PM  Aerie: 1Q Earnings Snapshot Associated Press
04:01PM  Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-03-19 02:42PM  Another $100 million 'safety net' set for this Triangle pharma American City Business Journals
May-02-19 06:33PM  Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M Business Wire
12:42PM  Heres What Hedge Funds Think About Aerie Pharmaceuticals Inc (AERI) Insider Monkey
May-01-19 12:00PM  With profits in sight, Durham pharma launches new trials American City Business Journals
06:30AM  Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives Business Wire
Apr-30-19 07:30AM  Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019 Business Wire
Apr-25-19 06:30AM  Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant Business Wire
Apr-11-19 10:05AM  Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside TheStreet.com
Apr-10-19 12:05PM  Have Insiders Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares This Year? Simply Wall St.
Apr-02-19 07:30AM  Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference Business Wire
Apr-01-19 06:30AM  Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe Business Wire
Mar-28-19 05:07PM  Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain? Zacks
Mar-27-19 09:30AM  Aerie (AERI) Down 2.9% Since Last Earnings Report: Can It Rebound? Zacks
Mar-25-19 06:30AM  Aerie Pharmaceuticals Announces Four Appointments Business Wire
Mar-22-19 11:23AM  Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan Zacks
Mar-21-19 06:30AM  Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing Business Wire +7.39%
Mar-19-19 12:28PM  Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105 Zacks
Mar-18-19 06:30AM  Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Business Wire
Mar-13-19 12:50PM  Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma Zacks
07:27AM  The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie Benzinga
Mar-12-19 06:30PM  Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance Business Wire
06:20PM  Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension Business Wire
Mar-07-19 08:13AM  Introducing Aerie Pharmaceuticals, The Stock That Zoomed 271% In The Last Three Years Simply Wall St.
Mar-05-19 07:30AM  Aerie Pharmaceuticals to Present at Two Investor Conferences in March Business Wire
Mar-01-19 08:25AM  New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
06:18AM  Edited Transcript of AERI earnings conference call or presentation 25-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kopczynski Casey C.Chief Scientific OfficerDec 03Option Exercise0.41117,00047,385218,511Dec 05 04:06 PM
RUBINO RICHARD JChief Financial OfficerSep 09Buy19.935,040100,447339,446Sep 09 05:45 PM
ANIDO VICENTE JRChief Executive OfficerSep 09Buy19.0126,250498,953197,631Sep 09 05:43 PM
Foresite Capital Management II10% OwnerSep 05Buy18.4215,700289,1942,350,477Sep 06 08:28 PM
Foresite Capital Management II10% OwnerSep 04Buy18.48100,2001,851,6962,334,777Sep 06 08:28 PM
Foresite Capital Management II10% OwnerSep 03Buy20.8150,0001,040,7412,325,477Sep 04 08:38 PM
Foresite Capital Management II10% OwnerAug 30Buy21.3625,000534,0002,275,477Sep 04 08:38 PM
Foresite Capital Management II10% OwnerAug 23Buy23.4238,300896,9862,250,477Aug 23 08:52 PM
Foresite Capital Management II10% OwnerAug 22Buy23.686,700158,6562,212,177Aug 23 08:52 PM
Foresite Capital Management II10% OwnerAug 21Buy23.251,15326,8072,205,477Aug 23 08:52 PM
Foresite Capital Management II10% OwnerAug 20Buy23.2150,0001,160,5002,204,324Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 19Buy23.343,84789,7892,154,324Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 16Buy24.23100,0002,423,0002,150,477Aug 20 08:27 PM
Foresite Capital Management II10% OwnerAug 14Buy23.73100,0002,373,0002,050,477Aug 14 08:15 PM
Foresite Capital Management II10% OwnerAug 13Buy25.35250,0006,337,3421,310,000Aug 14 08:15 PM
Foresite Capital Management II10% OwnerAug 12Buy24.43189,5554,630,8291,060,000Aug 14 08:15 PM
Kopczynski Casey C.Chief Scientific OfficerFeb 01Sale46.1711,000507,84495,743Feb 01 08:09 PM
Kopczynski Casey C.Chief Scientific OfficerJan 02Sale35.2111,000387,313106,743Jan 02 04:03 PM